Parasite | Eso | Sto | Cancer | ESD
[À§ÀüÀÌ. ÀüÀ̼º À§¾Ï. Gastric metastasis. Metastasis from gastric cancer.] - ðû
1. Introduction
3. Æó¾Ï À§ÀüÀÌ
5. Ç÷¾×Áúȯ À§ÀüÀÌ È¤Àº À§Ä§À±
8. References
´Ù¾çÇÑ ¾Ç¼ºÁúȯÀÌ À§·Î ÀüÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼ö³â Àü Elsevier¿¡¼ ³ª¿À´Â GI & Hepatology News (Korean Edition)¿¡ ±â°íÇÑ ³»¿ëÀÔ´Ï´Ù.
¿ì¸® ³ª¶ó¿¡¼´Â ¼±¸¿¡ ºñÇÏ¿© Èæ»öÁ¾ÀÌ µå¹® ÆíÀÌÁö¸¸, ºñ±³Àû ÁøÇàµÈ »óÅ·Π¹ß°ßµÇ´Â ¿¹°¡ ¸¹¾Æ¼ ¿¹ÈÄ´Â ºÒ·®ÇÏ´Ù. Èæ»öÁ¾Àº ¼ÒÈ°üÀ¸·Î Àß ÀüÀ̵Ǵ ´ëÇ¥ÀûÀÎ ¾Ç¼ºÁúȯÀ¸·Î, Èæ»öÁ¾À¸·Î »ç¸ÁÇÑ È¯ÀÚÀÇ 60%°¡ ºÎ°Ë¿¡¼ ¼ÒÈ°ü ÀüÀÌ°¡ ¹ß°ßµÈ´Ù. °¡Àå ÀüÀÌ ºóµµ°¡ ³ôÀº °÷Àº ¼ÒÀåÀÌÁö¸¸ ´ëÀå, À§, ½Äµµ µî¿¡µµ ÀüÀÌ°¡ ÈçÇÏ´Ù. À§·ÎÀÇ ÀüÀÌ´Â ¾à 10-26% Á¤µµÀÌ¸ç ´Ù¹ß¼º Á¡¸·ÇÏ Á¾¾çÀ¸·Î °üÂûµÇµÈ´Ù. ƯÈ÷ Á¡¸·ÇÏ Á¾¾ç »ó´ÜÀÇ depression°ú black discolorationÀÌ Æ¯Â¡ÀÌ´Ù. °£È¤ amelanotic melanomaµµ ÀÖÀ¸¹Ç·Î (ÀÌ °æ¿ì´Â blackÀÌ ¾Æ´Ï´Ù) ÁÖÀÇÇÒ ÇÊ¿ä°¡ ÀÖ´Ù. º» Áõ·Ê¿¡¼´Â ¾ó±¼ ÇǺο¡ Èæ»öÁ¾ÀÌ ÀÖ¾úÁö¸¸, ±¤¹üÀ§ÇÏ°Ô ÀüÀÌµÈ Èæ»öÁ¾ÀÇ 10% Á¤µµ¿¡¼´Â ¿ø¹ßºÎÀ§¸¦ ãÀ» ¼ö ¾ø´Ù°í ÇÑ´Ù (´ëÇѼÒȱ⳻½Ã°æÇÐȸÁö 2004;28:71-75). ÇÊÀÚµµ ÀüÀ̼º Èæ»öÁ¾À¸·Î Áø´ÜµÈ ȯÀÚÀÇ ¿ø¹ßºÎÀ§¸¦ ãÀ» ¼ö ¾ø¾ú´ø °æ¿ì°¡ ÀÖ¾ú´Âµ¥, ±× ȯÀÚ¿¡¼ ¼ö³â Àü ¾ó±¼ÀÇ Á¡À» »ÌÀº °ú°Å·ÂÀÌ ÀÖ¾ú±â ¶§¹®¿¡ Ȥ½Ã ¾ó±¼ÀÇ Á¡ÀÌ Èæ»öÁ¾À̾úÁö ¾Ê³ª ÀǽÉÇÏ¿´´ø ±â¾ïÀÌ ³´Ù.
Multiple metastasis ¼Ò°ßÀ¸·Î MUO work up Áß ³»½Ã°æ¿¡¼ pinpoint black spotÀÌ °üÂûµÇ¾î Á¶Á÷°Ë»ç¸¦ ÅëÇÏ¿© melanoma È®ÀÎÇÔ.
s/p STG d/t gastric cancer. Á¶Á÷°Ë»ç ¸ðµÎ metastatic melanoma
µÎÅë°ú blurred visionÀ¸·Î ³»¿øÇÑ È¯ÀÚÀÔ´Ï´Ù. ³ú MRI¿¡¼ ¡°Malignant bone mass such as skull base metastasis with hypoglossal canal involvement and denervation injury of tongue, right¡±ÀÇ ¼Ò°ßÀ̾ú°í PET¿¡¼ multiple metastasis°¡ °üÂûµÇ¾ú½À´Ï´Ù. À§³»½Ã°æ¿¡¼ À§Ã¼ºÎ¿Í ÀüÁ¤ºÎ¿¡¼ °ñ°í·ç ¸Å¿ì ¸¹Àº °ËÀº»ö Á¡µéÀÌ °üÂûµÇ¾ú°í Á¶Á÷°Ë»ç¿¡¼ malignant melanoma, HMB45 (+), S-100 (Focal +), cytokeratin (-)·Î È®ÀεǾú½À´Ï´Ù. µî¿¡¼ Á¡ÀÌ ¹ß°ßµÇ¾ú°í Á¶Á÷°Ë»ç¿¡¼ malignant melanoma¿´½À´Ï´Ù. Multiple metastasis°¡ ÀǽɵǾú´ø ȯÀÚ¿¡¼ À§³»½Ã°æÀ» ÅëÇÏ¿© melanoma°¡ È®ÀÎµÈ ÈÄ Àü½Å¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ½Åü°ËÁøÀ» ÅëÇÏ¿© ¿ø¹ßº´¼Ò¸¦ ¹ß°ßÇÑ °æ¿ìÀÔ´Ï´Ù. MelanomaÀÇ À§ÀüÀÌ´Â ÁÖ·Î SMT-likeÇÑ elevated lesionÀÌ dark pigmentationµÈ ÇüÅ·Πº¸ÀÔ´Ï´Ù. ¿À´ÃÀÇ Áõ·Ê´Â flat dark spotµé·Î °üÂûµÈ µå¹® ¿¹ÀÔ´Ï´Ù.
Anal melanoma recurrence with gastric metastasis
Melena·Î ³»¿øÇÏ¿© À§ÀüÀ̸¦ ¹ß°ßÇÏ¿´°í ±âŸ ´ÙÀå±â ÀüÀÌ°¡ ÀÖ¾úÀ½
[2017-1-12. ¸ñ¿ä³»½Ã°æÁý´ãȸ Áõ·Ê - Gastric metastasis from malignant melanoma]
µÎÅëÀ» ÁÖ¼Ò·Î °Ë»çÇÏ¿© lung cancer with brain metastasis·Î ÀÇ·ÚµÈ 70´ë ³²¼ºÀÔ´Ï´Ù. Lung biopsy (gun)Àº "poorly differentiated tumor with dyscohesive anaplastic cells. The possibility of malignant melanoma is suspected."¿´½À´Ï´Ù.
À§³»½Ã°æ Á¶Á÷°Ë»ç´Â ¾Æ·¡¿Í °°¾Ò½À´Ï´Ù.
Malignant melanona.
S-100: diffusely positive in tumor cells
Melanoma Ag (HMB45): diffusely positive in tumor cells
c-kit gene, BRAF gene: no mutation
ÀÌ È¯ÀÚ´Â skin lesionÀº ¾ø¾ú½À´Ï´Ù. µû¶ó¼ ãÁö ¸øÇÏ´Â skin melanomaÀÇ lung, brain, stomach metastasisÀÏ ¼öµµ ÀÖ°í, primary lung melanomaÀÇ multiple metastasisÀÏ ¼öµµ ÀÖÀ» °Í °°½À´Ï´Ù. Stage°¡ ³Ê¹« ³ô¾Æ Ä¡·á °èȹÀÌ ´Þ¶óÁú °ÍÀº ¾øÁö¸¸... ³»½Ã°æÀÇ»ç·Î¼ ƯÀÌÇÑ Á¡Àº melanoma stomach metastasisÀÇ »öÁ¶°¡ °ËÁö ¾Ê¾Ò´Ù´Â Á¡ÀÔ´Ï´Ù.
°ÇÁø¿¡¼ ¿ì¿¬È÷ ¹ß°ßµÈ µÎ °³ÀÇ °ËÀº Á¡. ¹Ýµå½Ã gastric melanomaÀϱî?
Æó¾Ï (large cell neuroendocrine carcinoma) À§ÀüÀÌ
À¯¹æ¾Ï À§ÀüÀÌ (º¸¸¸ 4Çü ÁøÇ༺ À§¾Ï°ú ºñ½ÁÇÑ ¸ð½À)
¾î¶² ±³°ú¼¿¡¼ °¡Á®¿Â ±×¸²ÀÔ´Ï´Ù. ¸é¿ªÇü±¤¿°»ö¿¡¼ estrogen (+) ¿´´Ù°í ÇÕ´Ï´Ù. À¯¹æ¾Ï À§ÀüÀÌ°¡ linitis plastica ¾ç»óÀ¸·Î ³ªÅ¸³ µå¹® °æ¿ìÀÔ´Ï´Ù.
´Ù¸¥ ȯÀÚ º´¸® »çÁø (³»½Ã°æ »çÁø not available). Poorly differentiated carcinoma
´Ù¸¥ ȯÀÚ º´¸® »çÁø (³»½Ã°æ »çÁø not available). GATA3 positive
´Ù¸¥ ȯÀÚ º´¸® »çÁø (³»½Ã°æ »çÁø not available). Estrogen receptor positive
Èä¼ö¿Í º¹¼ö¿Í peritoneal seedingÀ» º¸ÀÎ À¯¹æ¾Ï ȯÀÚ (2017). À§¿¡ À½½Ä¹°ÀÌ ³²¾ÆÀÖ¾ú°í antral deformity°¡ ÀÖ¾ú½À´Ï´Ù. À§ÀüÀÌ´Â ¾Æ´ÏÁö¸¸ º¹¸· ÀüÀÌ¿¡ µû¸¥ ÀÌÂ÷ÀûÀÎ Çö»óÀ¸·Î ÃßÁ¤µË´Ï´Ù.
5. Ç÷¾×Áúȯ À§ÀüÀÌ (ȤÀº À§Ä§À±)
¹éÇ÷º´ À§Ä§À±. ºñƯÀÌÀû À§ÀåÁõ¼¼¿Í üÁß°¨¼Ò¸¦ ÁÖ¼Ò·Î ³»¿øÇÑ ºÐÀÔ´Ï´Ù. CBC, chemistry¿Í ³»½Ã°æÀ» ó¹æÇÏ¿´°í Ç÷¾×°Ë»ç¿¡¼ ¹éÇ÷º´(AML)À¸·Î Áø´ÜµÇ¾ú°í, À§ÀüÁ¤ºÎ SMT ºñ½ÁÇÑ ºÎÀ§ÀÇ Á¶Á÷°Ë»ç¿Í À§Ã¼ºÎ ºñƯÀÌÀû ¹ßÀûºÎ Á¶Á÷°Ë»ç¿¡¼ myeloid blasts in lamina propria ¼Ò°ßÀ̾ú½À´Ï´Ù.
¹éÇ÷º´ À§Ä§À± (À§Á¶Á÷°Ë»ç: leukemic infiltration (myeloblastic sarcoma))
³¼Ò¾Ï º¹¸·ÀüÀÌ - À§¾Ï 798. CT¿¡¼ À§º® ºñÈÄ
³¼Ò¾Ï À§ÀüÀÌ - Vague abdominal discomfort, AST/ALT 176/129, renal infarction, digit embolizationÀ¸·Î ¹ßÇöÇÑ ovarian cancer with metastasis (CA125=2132)
ÃéÀå¾Ï À§Ä§À±. Upper GI bleedingÀ¸·Î ³»¿øÇÏ¿´´ø ȯÀÚÀÔ´Ï´Ù.
°£¼¼Æ÷¾Ï À§Ä§À± (direct invasion)
Stomach involvement by the recurrent mass after surgery (left trisectionectomy) for hilar cholangiocarcinoma 6 years ago (EndoTODAY ¸ñ¿ä³»½Ã°æÁý´ãȸ2017-3-16)
[2016-7-7. ¸ñ¿ä³»½Ã°æÁý´ãȸ Áõ·Ê]
Left lateral segmentÀÇ °£¼¼Æ÷¾ÏÀ¸·Î ¼ö¼úÀ» ½ÃÇà¹ÞÀº ȯÀÚÀÇ ¼ö¼ú Àü CT ¹× MRIÀÔ´Ï´Ù.
Liver, left lateral segmentectomy:
Progressed hepatocellular carcinoma, S2 and S3 :
1. Gross type : Nodular type
2. Differentiation : Edmondson grade III
3. Histologic type : microtrabecular
4. Cell type : hepatic
5. Tumor size : 10.1x8x5.7 cm
6. Tumor number : one
7. Fatty change : no
8. Tumor necrosis : yes (50%)
9. Hemorrhage : no
10. Fibrous capsule : partial
11. Tumor invasion in tumor capsule : yes
12. Septum formation : yes
13. Microvessel invasion : peritumoral
14. Portal vein invasion : no
15. Bile duct invasion : no
16. Intrahepatic metastasis (satellite nodule) : no
17. Multicentric occurrence : no
18. Surgical margin invasion : no (safety margin : 0.4 cm)
19. Serosa invasion : no
20. Pathologic T stage (modified UICC, 2000): pT3
21. Pathologic T stage (AJCC, 2010) : pT2
22. Regional lymph nodes : Metastasis in 8 out of 11 lymph nodes
23. Distant metastasis : not applicable
ÃßÀû°Ë»ç CT¿¡¼ Àç¹ßÀÌ È®ÀεǾú½À´Ï´Ù. "Remnant liver¿¡ multiple low-density lesionµéÀÌ »õ·Ó°Ô º¸¿© recurrent tumor·Î »ý°¢µÇ¸ç ¾çÃø portal vein ¹× main portal vein ³»¿¡ tumor thrombus°¡ Çü¼ºµÇ¾î ÀÖÀ½. Hepatoduodenal ligament¿Í pancreas ÁÖº¯ ±×¸®°í aorta ÁÖº¯À¸·Î metastatic lymph nodeµéÀÇ size°¡ ¸ðµÎ Áõ°¡µÇ¾úÀ½."
À§³»½Ã°æ¿¡¼µµ Àç¹ß¾ÏÀÇ À§Ä§À±ÀÌ ÀǽɵǾú°í Á¶Á÷°Ë»ç¿¡¼ ¾Æ·¡¿Í °°Àº ¼Ò°ßÀÌ ³ª¿Ô½À´Ï´Ù.
Poorly differentiated carcinoma with clear cells (see note)
Note: The possibility of clear cell type adenocarcinoma or hepatoid adenocarcinoma is suspicious. Based on immunohistochemistry findings, the former is preferred.
1) 2015³â ¾Æ»êº´¿ø¿¡¼ ¹ßÇ¥ÇÑ ´Ù¾çÇÑ À§ÀüÀÌ¿¡ ´ëÇÑ ³í¹®ÀÔ´Ï´Ù (Kim GH. Gut Liver 2015). »çÁøÀ» ¾Æ·¡¿¡ ¿Å±é´Ï´Ù.
© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng. (since 1999-8-23)